Biotechnology start-up Next Science (ASX: NXS) recorded strong sales growth in 2018 as acceptance grew of its novel technologies to kill bacteria.
The Sydney company reported sales of $6.1 million for the year of its Xbio technology products which attack the biofilm that surrounds and protects bacteria.
Four of its products have secured US FDA approval, including SurgX antimicrobial surgical gel (pictured), and an open surgery wash called Bactisure.
The company has submitted a dossier seeking FDA approval for a topical skin cancer treatment for Actinic Ketosis and superficial Basal Cell Carcinomas.
And an acne treatment, which has secured a US patent, is distributed in Australia.
Xbio managing director Judith Mitchell said there had been an expansion of knowledge in understanding biofilms and the health issues they caused.
She said: “The outcomes from using our products have been second to none in addressing these issues for physicians and surgeons in treating their patients.”
Mitchell said the company would continue to benefit from the direct distribution network it had established in the United States.
“With upcoming EU product approvals, exciting ongoing trials, and a highly prospective pipeling of new products targeting large markets, our opportunity set has increased.”
Picture: Next Science
Subscribe to our free @AuManufacturing newsletter here.